-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

Benzinga·08/27/2025 16:22:29
Listen to the news
Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and raises the price target from $10 to $25.